Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reem Alsolami

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Personalized Medicine|March 11, 2014
Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Reem Alsolami, Samantha Jl Knight, Anna Schuh
Pharmaceuticals (Basel, Switzerland)|September 28, 2024
Computational Design and Optimization of Peptide Inhibitors for SIRT2Heba A Alkhatabi, Fatmah M A Naemi, Reem Alsolami, et al.
Immunology Letters|August 16, 2024
Acute and prolonged effects of interleukin-33 on cytokines in human cord blood-derived mast cellsSherin Bakhashab, Ghalya H Banafea, Farid Ahmed, et al.
Plos One|October 21, 2024
Acute and chronic impact of interleukin-33 stimulation on chemokines and growth factors in human cord blood-derived mast cellsSherin Bakhashab, Ghalya H Banafea, Farid Ahmed, et al.
Nanomaterials (Basel, Switzerland)|March 12, 2024
Correction: Jamal et al. Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells. <i>Nanomaterials</i> 2022, <i>12</i>, 4029Alam Jamal, Amer H Asseri, Ehab M M Ali, et al.
Nanomaterials (Basel, Switzerland)|November 26, 2022
Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer CellsAlam Jamal, Amer H Asseri, Ehab M M Ali, et al.
International Journal of General Medicine|January 11, 2024
Application of Newly Customized Myeloid NGS Panel in the Diagnosis of Myeloid MalignanciesHeba A Alkhatabi, Wejdan Alqahtani, Reem Alsolami, et al.
Blood|August 29, 2015
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLLRomain Guièze, Pauline Robbe, Ruth Clifford, et al.
Nature Genetics|November 5, 2022
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical featuresPauline Robbe, Kate E Ridout, Dimitrios V Vavoulis, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Personalized Medicine|March 11, 2014
Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Reem Alsolami, Samantha Jl Knight, Anna Schuh
Pharmaceuticals (Basel, Switzerland)|September 28, 2024
Computational Design and Optimization of Peptide Inhibitors for SIRT2Heba A Alkhatabi, Fatmah M A Naemi, Reem Alsolami, et al.
Immunology Letters|August 16, 2024
Acute and prolonged effects of interleukin-33 on cytokines in human cord blood-derived mast cellsSherin Bakhashab, Ghalya H Banafea, Farid Ahmed, et al.
Plos One|October 21, 2024
Acute and chronic impact of interleukin-33 stimulation on chemokines and growth factors in human cord blood-derived mast cellsSherin Bakhashab, Ghalya H Banafea, Farid Ahmed, et al.
Nanomaterials (Basel, Switzerland)|March 12, 2024
Correction: Jamal et al. Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells. <i>Nanomaterials</i> 2022, <i>12</i>, 4029Alam Jamal, Amer H Asseri, Ehab M M Ali, et al.
Nanomaterials (Basel, Switzerland)|November 26, 2022
Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer CellsAlam Jamal, Amer H Asseri, Ehab M M Ali, et al.
International Journal of General Medicine|January 11, 2024
Application of Newly Customized Myeloid NGS Panel in the Diagnosis of Myeloid MalignanciesHeba A Alkhatabi, Wejdan Alqahtani, Reem Alsolami, et al.
Blood|August 29, 2015
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLLRomain Guièze, Pauline Robbe, Ruth Clifford, et al.
Nature Genetics|November 5, 2022
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical featuresPauline Robbe, Kate E Ridout, Dimitrios V Vavoulis, et al.
Pageof 1